MARATTO

article · AIDS Care

Interest in long-acting injectable antiretroviral therapy (ART) among adults living with HIV newly starting or restarting ART in Cape Town, South Africa

Abstract

Long-acting injectable antiretroviral therapy (LAI ART) has proven effective in maintaining viral suppression among people living with HIV but recommendations to switch to LAI ART are limited to individuals stable and virologically suppressed on oral ART. Understanding LAI perceptions among diverse populations living with HIV is essential. In a cross-sectional survey at two peri-urban clinics in Cape Town, adults starting or restarting treatment rated their hypothetical interest in LAI ART on a quantitative Likert-scale (1= not at all interested to 5 = very interested) and provided open-ended explanations. Among 329 participants (61% women; median age 39 years), 74% were very interested, 15% were unsure or somewhat interested (response 3 or 4) and 11% were not very or not at all interested (response 1 or 2). In thematic analysis of open-ended responses, participants commonly viewed LAI ART as a way to avoid daily pills, reduce adherence-related stress, and maintain privacy, noting that injections offered convenience and discretion. Concerns centred on fear of injections, potential side effects, and desire to hear others' experiences before deciding. The substantial interest observed suggests, once accessible, LAI ART as a treatment option in this population could move us closer to individual- and population-level HIV treatment goals.

Research topics

  • HIV/AIDS Research and Interventions
  • HIV Research and Treatment
  • HIV, Drug Use, Sexual Risk

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1080/09540121.2026.2682339

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.